TICKERNERD
Menu
MEDMEDConsumer Cyclical · Personal Services

MED Stock Forecast: Medifast, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$12
−0.90% on the day

The 1 Wall Street analysts covering Medifast, Inc. hold a median 12-month price target of $12 — -1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$135.9M
Ticker Nerd rank
48/ 100
Median analyst target
$12
Analysts covering
1
Revenue$76.4M−27.6% y/y
Operating income−$4.3M
Net income−$3.1M
Free cash flow$728K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
+5.5%
YTD
+13.8%
1Y
+0.1%
From 52W high
−7.6%
From 52W low
+28.6%
$9
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medifast, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Revisions
87
Size
71
Momentum
44
Quality
36
Volatility
36
Issuance
32
Growth
28
Value
6

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$9$10$11$12$13Jan 26Apr 26Jul 26Oct 26MEDHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits −1.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Feb 2026Stephens & Co.MaintainsEqual-Weight$15 → $12
19 Feb 2026Stephens & Co.MaintainsEqual-Weight—
19 Feb 2025DA DavidsonMaintainsNeutral—
5 Nov 2024DA DavidsonUpgradeNeutral—
22 July 2024DA DavidsonMaintainsUnderperform—
5 June 2024DA DavidsonDowngradeUnderperform—
30 Apr 2024DA DavidsonMaintainsNeutral—
21 Feb 2024DA DavidsonMaintainsNeutral—
13 Oct 2023Stephens & Co.InitiatesEqual-Weight—
8 Aug 2023DA DavidsonMaintainsNeutral—
31 July 2023DA DavidsonMaintainsNeutral—
2 May 2023DA DavidsonMaintainsNeutral—
22 Feb 2023DA DavidsonMaintainsNeutral—
4 Nov 2022DA DavidsonDowngradeNeutral—
4 Aug 2022DA DavidsonMaintainsBuy—
4 Aug 2022JefferiesDowngradeHold—
2 June 2022DA DavidsonMaintainsBuy—
24 Feb 2022DA DavidsonMaintainsBuy—
8 Nov 2021DA DavidsonMaintainsBuy—
5 May 2021DA DavidsonMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MED appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Medifast, Inc. returned +0.1% against +12.4% for the S&P 500, dividends included.

MED vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26MEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Medifast, Inc. (MED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
531.5×

Cheaper than 1% of US stocks

Price / sales
0.5×

Cheaper than 82% of US stocks

Price / book
0.7×

Cheaper than 78% of US stocks

EV / EBITDA
1.2×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−19.4%

Higher than 12% of US stocks

Earnings growth (YoY)
−27.6%

Higher than 17% of US stocks

Gross margin
69.9%

Higher than 82% of US stocks

Operating margin
−26.9%

Higher than 20% of US stocks

Net margin
−13.6%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−20.7%

Higher than 31% of US stocks

Return on assets
−8.6%

Higher than 28% of US stocks

Dividend yield
54.0%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Medifast, Inc. (MED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Medifast, Inc. has a market value of $135.9M and an enterprise value of −$25.4M.

  • Revenue in the twelve months to 30 June 2026: $316.9M. The latest quarter shrank 19.4% year on year.

  • Net income over the same four quarters: −$25.6M, a −8.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.33.

  • Free cash flow in the twelve months to 30 June 2026: $4.0M.

  • Medifast, Inc. spent $813K on share buybacks and $170K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 11.2M.

  • Trailing P/E: 531.5×; forward P/E: −303.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 53.97%, paying out 0% of earnings.

  • Medifast, Inc. employs 380 people — $834K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

MED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPersonal Services
CompanyMarket capTKN rank
MEDMedifast, Inc.$135.9M48
RGSRegis Corp.$74.1M78
CSVCarriage Services, Inc.$549.6M30
BFAMBright Horizons Family Solutions, Inc.$2.7B40
PLBYPlayboy, Inc.*$135.5M50
LVWRLiveWire Group, Inc.*$135.6M25
VNCEVince Holding Corp.*$138.1M99

* Nearest Consumer Cyclical names by size — few personal services companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medifast, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MED news & analysis

Medifast Is Running The Same Playbook, And I Have The Same Concerns

Seeking Alpha · 28 Oct 2026negative

Medifast reported Q3 2026 revenue down 19.4% year over year to $72 million, while active earning coaches fell 47% and average revenue per coach rose. The excerpt also notes management transition and activist involvement, with the core product and distribution model unchanged.

Why it matters — The revenue and coach declines, alongside ongoing GLP-1 disruption, highlight continuing challenges in Medifast’s business despite its cash-heavy balance sheet and board-level changes.

Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises

Zacks Investment Research · 27 Oct 2026positive

Medifast topped Q3 earnings expectations, with a narrower-than-expected loss as coach productivity rose 54.1% and margins expanded. Revenue declined and the coach network shrank.

Why it matters — MED watchers may note the stronger coach productivity and margins alongside continued revenue and network contraction.

Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript

Seeking Alpha · 26 Oct 2026neutral

The item is a transcript of Medifast, Inc.’s Q3 2026 earnings call. The provided excerpt contains no further details about the call.

Why it matters — MED watchers may consult the transcript for management commentary, but the excerpt provides no specific results or business updates.

What Medifast (MED) Said on Its Q3 Earnings Call

MarketBeat · 26 Oct 2026negative

Medifast reported third-quarter 2026 revenue of $72 million, down 19.4% year over year, amid a sharp decline in its active earning coach base. Management said revenue was within guidance and sales had stabilized around the mid-$70 million range for a fourth consecutive quarter.

Why it matters — The results highlight ongoing revenue pressure linked to the decline in active earning coaches, alongside management’s report of recent sales stabilization.

Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research · 26 Oct 2026positive

Medifast reported a third-quarter loss of $0.19 per share, compared with the Zacks Consensus Estimate of a $0.40 loss and a $0.21 loss per share a year earlier. The headline also says the company topped revenue estimates.

Why it matters — The reported per-share loss was smaller than the consensus estimate and the year-ago loss, while the headline indicates revenue exceeded estimates.

FAQ

Frequently asked questions about MED stock

What is the MED stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Medifast, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MED stock a buy right now?

Of the 1 analysts covering Medifast, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medifast, Inc. 48 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MED?

As at 31 Oct 2026, Medifast, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will MED stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies -1.2% from the last close, and Ticker Nerd's factor model ranks Medifast, Inc. 48 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MED stock forecast for 2030?

No analyst covering Medifast, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has MED stock performed over the past year?

Medifast, Inc. returned +0.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medifast, Inc. do?

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health.

What is the latest news on MED?

The most recent item we track (Seeking Alpha, 28 Oct 2026): "Medifast Is Running The Same Playbook, And I Have The Same Concerns". Medifast reported Q3 2026 revenue down 19.4% year over year to $72 million, while active earning coaches fell 47% and average revenue per coach rose. The excerpt also notes management transition and activist involvement, with the core product and distribution model unchanged.

Company

About Medifast, Inc.

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health. The company’s core offering centers on the OPTAVIA brand, which combines structured nutrition products, meal replacements, and coaching support to help customers build healthier daily routines. Medifast Inc. sells a range of products including shakes, bars, soups, cereals, and other nutrition items designed for convenience and consistency within its program model. Its business serves individuals seeking weight loss and long-term healthy living support, while also relying on a network of independent coaches and digital ordering channels to deliver its services. Headquartered in Baltimore, Maryland, Medifast Inc. plays a specialized role in the broader wellness market by integrating products, guidance, and behavior-change support into a single customer experience.

CEO Mr. Nicholas M. Johnson · 380 employees · United States · https://medifastinc.com